Analysts Bullish on Guardant Health, New Relic, OPAL Fuels; Diana Shipping Beats Estimates
- May 26th, 2023
- 84 views
Diana Shipping Inc. (NYSE: DSX) has released its financial results for the first quarter of 2023, reporting earnings per share (EPS) of $0.22, surpassing the consensus estimate of $0.14. In light of its performance, the company has declared a dividend of $0.15 per share on its common stock, reflecting the positive results achieved during the quarter.
In pre-market, $DSX is currently experiencing an increase of $0.10 (+2.79%), trading at $3.67.
Meanwhile, Guardant Health, Inc. (Nasdaq: GH) has received an upgrade from Citigroup, moving from Neutral to Buy. The price target for $GH has also been raised from $28 to $40.
$GH is showing a significant rise of $1.72 (+6.17%), currently trading at $29.59 in pre-market.
Similarly, New Relic, Inc. (NYSE: NEWR) has received an upgrade from RBC Capital Markets, moving from Sector Perform to Outperform. The price target for $NEWR has been raised from $75 to $95.
$NEWR is exhibiting an increase of $2.51 (+3.21%) in pre-market, currently trading at $80.75.
Additionally, OPAL Fuels Inc. (Nasdaq: OPAL) has been initiated with a Buy rating and a price target of $13 at Janney Montgomery Scott. This suggests a positive outlook for $OPAL and its potential growth in the market.
In pre-market, $OPAL is showing an upward trend with an increase of $0.28 (+4.58%), currently trading at $6.40.
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)
Post Your Comments
Want To Find Some News?
Jazz Pharma, Zymeworks: Promising Data on Zanidatamab in HER2-Amplified BTC; Positive View on Trade Desk, Kura Sushi and Surgery PartnersJune 03rd, 2023
Globus Maritime: Profits, Revenue Decline YoY; Analysts See Opportunity in Paychex, Fluence Energy, Quaker and MovellaJune 02nd, 2023
Chijet Motor Debuts on Nasdaq, Market Experts Bullish on Ambrx, FibroGen, Bowlero, REGENXBIO and KopinJune 02nd, 2023